Literature DB >> 24131336

Vitiligo and alopecia areata: apples and oranges?

John E Harris1.   

Abstract

Vitiligo and alopecia areata are common autoimmune diseases of the skin. Vitiligo is caused by the destruction of melanocytes and results in the appearance of white patches on any part of the body, while alopecia areata is characterized by patchy hair loss primarily on the scalp, but may also involve other areas as well. At first glance, the two diseases appear to be quite different, targeting different cell types and managed using different treatment approaches. However, the immune cell populations and cytokines that drive each disease are similar, they are closely associated within patients and their family members, and vitiligo and alopecia areata have common genetic risk factors, suggesting that they share a similar pathogenesis. Like apples and oranges, vitiligo and alopecia areata have some obvious differences, but similarities abound. Recognizing both similarities and differences will promote research into the pathogenesis of each disease, as well as the development of new treatments.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IFN-γ; T cell; adaptive immunity; alopecia areata; autoantigen; autoimmunity; cytokine; innate immunity; treatment; vitiligo

Mesh:

Year:  2013        PMID: 24131336      PMCID: PMC3867815          DOI: 10.1111/exd.12264

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  70 in total

1.  Trichohyalin is a potential major autoantigen in human alopecia areata.

Authors:  Man Ching Leung; Chris W Sutton; David A Fenton; Desmond J Tobin
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

2.  Alopecia areata induced in C3H/HeJ mice by interferon-gamma: evidence for loss of immune privilege.

Authors:  Amos Gilhar; Yossi Kam; Bedia Assy; Richard S Kalish
Journal:  J Invest Dermatol       Date:  2005-01       Impact factor: 8.551

3.  Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study.

Authors:  Bruce E Strober; Kimberly Siu; Andrew F Alexis; Gene Kim; Ken Washenik; Animesh Sinha; Jerome L Shupack
Journal:  J Am Acad Dermatol       Date:  2005-06       Impact factor: 11.527

4.  An unusual anatomical colocalization of alopecia areata and vitiligo in a child, and improvement during treatment with topical prostaglandin E2.

Authors:  S Yadav; S Dogra; I Kaur
Journal:  Clin Exp Dermatol       Date:  2009-12       Impact factor: 3.470

5.  Activation of the unfolded protein response in vitiligo: the missing link?

Authors:  Thierry Passeron; Jean-Paul Ortonne
Journal:  J Invest Dermatol       Date:  2012-11       Impact factor: 8.551

6.  Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study.

Authors:  Szu-Ying Chu; Yi-Ju Chen; Wei-Cheng Tseng; Ming-Wei Lin; Tzeng-Ji Chen; Chian-Yaw Hwang; Chih-Chiang Chen; Ding-Dar Lee; Yun-Ting Chang; Wen-Jen Wang; Han-Nan Liu
Journal:  J Am Acad Dermatol       Date:  2011-05-25       Impact factor: 11.527

7.  Th17 cells and activated dendritic cells are increased in vitiligo lesions.

Authors:  Claire Q F Wang; Andres E Cruz-Inigo; Judilyn Fuentes-Duculan; Dariush Moussai; Nicholas Gulati; Mary Sullivan-Whalen; Patricia Gilleaudeau; Jules A Cohen; James G Krueger
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

8.  An extraordinary colocalization of alopecia areata and vitiligo.

Authors:  Yuval Ramot; Elena Thomaidou; Alexander Mali; Abraham Zlotogorski
Journal:  Int J Trichology       Date:  2010-07

9.  Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo.

Authors:  Anna Wańkowicz-Kalińska; René M J G J van den Wijngaard; Bert J Tigges; Wiete Westerhof; Graham S Ogg; Vincenzo Cerundolo; Walter J Storkus; Pranab K Das
Journal:  Lab Invest       Date:  2003-05       Impact factor: 5.662

10.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.

Authors:  Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307

View more
  13 in total

1.  Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Ann Transl Med       Date:  2015-12

2.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

Review 3.  Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Authors:  A Sterkens; J Lambert; A Bervoets
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

Review 4.  Next generation human skin constructs as advanced tools for drug development.

Authors:  H E Abaci; Zongyou Guo; Yanne Doucet; Joanna Jacków; Angela Christiano
Journal:  Exp Biol Med (Maywood)       Date:  2017-06-07

Review 5.  Hair Follicle Melanocytes Initiate Autoimmunity in Alopecia Areata: a Trigger Point.

Authors:  Bo Xie; Jiayi Sun; Xiuzu Song
Journal:  Clin Rev Allergy Immunol       Date:  2022-09-19       Impact factor: 10.817

6.  Hair Follicle Melanogenesis Reflected in Hair Pigmentation as a Developmental Factor in Alopecia Areata.

Authors:  Margit Juhasz; Rosalynn R Z Conic; Natasha Atanaskova Mesinkovska
Journal:  Skin Appendage Disord       Date:  2021-06-03

Review 7.  Understanding autoimmunity of vitiligo and alopecia areata.

Authors:  Jillian F Rork; Mehdi Rashighi; John E Harris
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856

8.  Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review.

Authors:  Ki-Hun Kim; Woo-Young Sim; Bark-Lynn Lew
Journal:  Ann Dermatol       Date:  2021-05-04       Impact factor: 1.444

9.  Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.

Authors:  Rena C Zuo; Haley B Naik; Seth M Steinberg; Kristin Baird; Sandra A Mitchell; Zoya Kuzmina; Steven Z Pavletic; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2015-01       Impact factor: 10.282

10.  A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.

Authors:  Shahnawaz D Jadeja; Mohmmad Shoab Mansuri; Mala Singh; Mitesh Dwivedi; Naresh C Laddha; Rasheedunnisa Begum
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.